M&A Deal Summary |
|
|---|---|
| Date | 2014-06-24 |
| Target | Chelsea Therapeutics International |
| Sector | Life Science |
| Buyer(s) | H. Lundbeck |
| Deal Type | Going Private |
| Deal Value | 658M USD |
| Advisor(s) | Moelis & Co. Deutsche Bank Corporate & Investment Banking Torreya Partners (Financial) Morgan Lewis (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1915 |
| Sector | Healthcare Services |
| Employees | 5,681 |
| Revenue | 19.9B DKK (2023) |
H. Lundbeck A/S is an international pharmaceutical company engaged inthe research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. H. Lundbeck was founded in 1915 and is based in Valby, Denmark.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 6 |
| Sector (Life Science) | 2 of 6 |
| Type (Going Private) | 1 of 1 |
| State (North Carolina) | 1 of 1 |
| Country (United States) | 2 of 5 |
| Year (2014) | 1 of 1 |
| Size (of disclosed) | 4 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-01-21 |
Lundbeck - Portfolio Of Products
United States Lundbeck - Portfolio Of Products include Panhematin (haemin for injection) for the amelioration of recurrent attacks of acute intermittent porphyria. Other important drugs are NeoProfen (ibuprofen lysine injection) and Indocin I.V. (indomethacin injection), indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, and Cosmegen® (dactinomycin for injection) used mainly in the treatment of three rare cancers. |
Sell | $100M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-03-16 |
Prexton Therapeutics BV
Kloosterstraat 9, Netherlands Prexton Therapeutics BV is a biopharmaceutical company, One of the major objectives of research into new treatments for Parkinson’s disease is to find alternatives to the stimulation of the dopaminergic system through L-DOPA and dopamine agonists with the adverse effects linked to their long-term use. One target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. Some academic groups have demonstrated that novel mGluR4 positive allosteric modulators (PAMs) could – if not reverse – at least stop the progress of the disease. |
Buy | €100M |
